JP6804790B1 - Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途 - Google Patents

Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途 Download PDF

Info

Publication number
JP6804790B1
JP6804790B1 JP2020524817A JP2020524817A JP6804790B1 JP 6804790 B1 JP6804790 B1 JP 6804790B1 JP 2020524817 A JP2020524817 A JP 2020524817A JP 2020524817 A JP2020524817 A JP 2020524817A JP 6804790 B1 JP6804790 B1 JP 6804790B1
Authority
JP
Japan
Prior art keywords
optionally substituted
amino
alkyl
alkoxy
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020524817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021505530A (ja
Inventor
ジョージ アール． ペインター，
ジョージ アール． ペインター，
グレゴリー アール． ブルームリング，
グレゴリー アール． ブルームリング，
マイケル ジー． ナチュス，
マイケル ジー． ナチュス，
デイビッド ガスリー，
デイビッド ガスリー，
Original Assignee
エモリー ユニバーシティー
エモリー ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エモリー ユニバーシティー, エモリー ユニバーシティー filed Critical エモリー ユニバーシティー
Application granted granted Critical
Publication of JP6804790B1 publication Critical patent/JP6804790B1/ja
Publication of JP2021505530A publication Critical patent/JP2021505530A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2020524817A 2017-12-07 2018-12-07 Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途 Active JP6804790B1 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762595907P 2017-12-07 2017-12-07
US62/595,907 2017-12-07
US201862626998P 2018-02-06 2018-02-06
US62/626,998 2018-02-06
US201862760434P 2018-11-13 2018-11-13
US62/760,434 2018-11-13
PCT/US2018/064503 WO2019113462A1 (en) 2017-12-07 2018-12-07 N4-hydroxycytidine and derivatives and anti-viral uses related thereto

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020195927A Division JP7179372B2 (ja) 2017-12-07 2020-11-26 Ｎ４－ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途

Publications (2)

Publication Number Publication Date
JP6804790B1 true JP6804790B1 (ja) 2020-12-23
JP2021505530A JP2021505530A (ja) 2021-02-18

Family

ID=66751806

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020524817A Active JP6804790B1 (ja) 2017-12-07 2018-12-07 Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
JP2020195927A Active JP7179372B2 (ja) 2017-12-07 2020-11-26 Ｎ４－ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
JP2021106296A Active JP7305205B2 (ja) 2017-12-07 2021-06-28 Ｎ４－ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
JP2023062657A Pending JP2023082213A (ja) 2017-12-07 2023-04-07 Ｎ４－ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020195927A Active JP7179372B2 (ja) 2017-12-07 2020-11-26 Ｎ４－ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
JP2021106296A Active JP7305205B2 (ja) 2017-12-07 2021-06-28 Ｎ４－ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
JP2023062657A Pending JP2023082213A (ja) 2017-12-07 2023-04-07 Ｎ４－ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途

Country Status (27)

Country Link
US (3) US11331331B2 (enExample)
EP (2) EP3706762B1 (enExample)
JP (4) JP6804790B1 (enExample)
KR (3) KR20240011880A (enExample)
CN (2) CN111372592A (enExample)
AU (2) AU2018378832B9 (enExample)
BR (1) BR122022008466B1 (enExample)
CA (1) CA3082191C (enExample)
DK (1) DK3706762T3 (enExample)
ES (1) ES2995458T3 (enExample)
FI (1) FI3706762T3 (enExample)
GB (2) GB2581936B (enExample)
HR (1) HRP20241620T1 (enExample)
HU (1) HUE069306T2 (enExample)
IL (2) IL274155B (enExample)
LT (1) LT3706762T (enExample)
MX (2) MX2020005392A (enExample)
PH (2) PH12022550371A1 (enExample)
PL (1) PL3706762T3 (enExample)
PT (1) PT3706762T (enExample)
RS (1) RS66222B1 (enExample)
RU (1) RU2020116571A (enExample)
SA (1) SA520412305B1 (enExample)
SG (1) SG11202004403QA (enExample)
SI (1) SI3706762T1 (enExample)
WO (1) WO2019113462A1 (enExample)
ZA (1) ZA202002849B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107427529A (zh) * 2014-12-26 2017-12-01 埃莫里大学 N4‑羟基胞苷和衍生物及与其相关的抗病毒用途
JP2020518578A (ja) 2017-05-01 2020-06-25 ギリアード サイエンシーズ， インコーポレイテッド （Ｓ）−２−エチルブチル２−（（（Ｓ）−（（（２Ｒ，３Ｓ，４Ｒ，５Ｒ）−５−（４−アミノピロロ［２，１−ｆ］［１，２，４］トリアジン−７−イル）−５−シアノ−３，４−ジヒドロキシテトラヒドロフラン−２−イル）メトキシ）（フェノキシ）ホスホリル）アミノ）プロパノエートの結晶形態
ES2995458T3 (en) * 2017-12-07 2025-02-10 Univ Emory N4-hydroxycytidine derivative and anti-viral uses related thereto
CN112390838A (zh) * 2019-08-14 2021-02-23 斯微(上海)生物科技有限公司 一种改性核苷及其合成方法
WO2021050956A1 (en) * 2019-09-11 2021-03-18 The Scripps Research Institute Antiviral prodrugs and pharmaceutical compositions thereof
PE20230466A1 (es) * 2020-02-07 2023-03-14 Univ Emory N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos
CN111285911B (zh) * 2020-02-26 2021-04-02 山东大学 Gem-1mt两亲小分子化合物及其制剂、制备方法和应用
TWI890963B (zh) 2020-03-12 2025-07-21 美商基利科學股份有限公司 1'-氰基核苷之製備方法
WO2021203055A1 (en) * 2020-04-03 2021-10-07 Selva Therapeutics, Inc. Viral entry inhibitors and rna polymerase inhibitors
US11376232B2 (en) 2020-04-21 2022-07-05 Immunic Ag Vidofludimus for use in the treatment or prevention of viral diseases
US12097212B2 (en) 2020-06-08 2024-09-24 Brigham Young University Use of cationic steroidal antimicrobial compounds to deactivate coronavirus
US20240025938A1 (en) * 2020-08-27 2024-01-25 Emory University Novel forms of antiviral nucleosides
US20230270669A1 (en) * 2020-09-04 2023-08-31 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
US11702440B2 (en) * 2020-12-10 2023-07-18 Optimus Drugs Private Limited Pharmaceutical polymorphs of Molnupiravir
WO2022133323A1 (en) * 2020-12-18 2022-06-23 Southern Research Institute 6-aza-nucleoside prodrugs as antiviral agents for treating virus infections
EP4262816A4 (en) * 2020-12-18 2024-05-15 Merck Sharp & Dohme LLC PRODUCTION OF ANTIVIRAL NUCLEOSIDES
CN112608357B (zh) * 2020-12-21 2022-12-09 杭州科巢生物科技有限公司 一种抗病毒药物Molnupiravir的制备方法
CN112778387A (zh) * 2021-01-15 2021-05-11 杭州科巢生物科技有限公司 一种Molnupiravir晶型A及其制备方法
WO2022168106A1 (en) * 2021-02-06 2022-08-11 Fermenta Biotech Limited Chemo-enzymatic process for synthesis of molnupiravir
WO2022168107A1 (en) * 2021-02-06 2022-08-11 Fermenta Biotech Limited Enzymatic synthesis of molnupiravir intermediate
CN112552288A (zh) * 2021-02-19 2021-03-26 南京桦冠生物技术有限公司 一种4-肟-5`-（2-甲基丙酰基）尿苷的制备方法
CN113072606A (zh) * 2021-03-18 2021-07-06 南京正济医药研究有限公司 一种n4-羟基胞苷类化合物的晶型及其制备方法与用途
US11312743B1 (en) * 2021-03-20 2022-04-26 Optimus Drugs Private Limited Process for molnupiravir
WO2022208156A1 (en) * 2021-03-29 2022-10-06 Optimus Pharma Private Limited Pharmaceutical composition of molnupiravir
EP4320100A1 (en) 2021-04-09 2024-02-14 Immunic AG Deuterated dhodh inhibitors
CN115215914B (zh) * 2021-04-15 2024-05-28 中国科学院上海药物研究所 核苷类似物及其用途
US11407779B1 (en) 2021-04-23 2022-08-09 Divi's Laboratories Ltd. Process for the preparation of molnupiravir
CN113307834A (zh) * 2021-04-23 2021-08-27 安徽贝克联合制药有限公司 一种核糖核苷类似物的多晶型物、其制备方法及应用
WO2022265964A1 (en) * 2021-06-14 2022-12-22 VenatoRx Pharmaceuticals, Inc. Orally-bioavailable nucleoside analogs
CN113278040B (zh) * 2021-06-16 2022-07-05 苏州立新制药有限公司 5’-异丁酰基-n4-羟基胞苷的制备方法
WO2022262845A1 (en) * 2021-06-18 2022-12-22 Suzhou Spring-Sea Bio-Pharmaceuticals Co., Ltd. Ester derivatives of n4-hydroxycytidine and use thereof
CN113321694A (zh) * 2021-06-22 2021-08-31 药康众拓(江苏)医药科技有限公司 N4-羟基胞苷衍生物及其制备方法和用途
CN113433242B (zh) * 2021-06-28 2022-12-27 成都大学 Molnupiravir含量及有关物质的检测方法
CN113278041B (zh) * 2021-07-16 2021-10-19 南京颐媛生物医学研究院有限公司 一种核苷磷酸酯及其合成方法与抗肝炎病毒的制药应用
CN113735929A (zh) * 2021-07-21 2021-12-03 海化生命(厦门)科技有限公司 一种抗冠状病毒的化合物及其制备方法与应用
MX2024001645A (es) 2021-08-06 2024-02-27 Intervet Int Bv Metodo para el tratamiento de las enfermedades virales veterinarias.
CN115960148B (zh) * 2021-08-27 2023-12-12 南京知和医药科技有限公司 一种新型的胞苷衍生物及其药物组合物和用途
JP2024170686A (ja) * 2021-10-19 2024-12-11 興和株式会社 新規医薬
WO2023067623A1 (en) * 2021-10-20 2023-04-27 Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Of Soc. Act (Act Xxi Of 1860) A short and cost effective synthetic route towards anti viral eidd-1931 and its hydrate polymorphs
CN114085259A (zh) * 2021-10-21 2022-02-25 苏州立新制药有限公司 N4-羟基胞苷一水合物及其晶型b与制备方法和用途
CN113880902A (zh) * 2021-10-26 2022-01-04 江苏睿实生物科技有限公司 一种Molnupiravir药物中间体及其制备方法
EP4426315A1 (en) 2021-11-01 2024-09-11 Immunic AG Medical use of n4-hydroxy citicoline compounds
CN113929724B (zh) * 2021-11-02 2024-05-31 周雨恬 一种核苷类化合物及其药物组合物和用途
CN114306254B (zh) * 2021-11-30 2023-11-03 南京正济医药研究有限公司 一种Molnupiravir口服固体制剂及其制备方法
CN116217632A (zh) * 2021-12-06 2023-06-06 广州谷森制药有限公司 一种氘代胞苷衍生物的制备方法
WO2023111683A1 (en) * 2021-12-16 2023-06-22 Ascletis Bioscience Co., Ltd. N4-hydroxycytidine derivatives and use thereof as antiviral agent
US11541071B1 (en) * 2021-12-16 2023-01-03 Ascletis BioScience Co., Ltd Nucleoside derivatives and methods of use thereof
CN118488831A (zh) 2021-12-23 2024-08-13 苏宾特罗有限公司 包含油酸的新抗病毒组合物
UY40087A (es) 2021-12-23 2023-06-30 Immunic Ag Inhibidores de DHODH que contienen un bioisóstero de ácido carboxílico.
CN114507266A (zh) * 2022-01-24 2022-05-17 海门品尚医药科技有限公司 一种Molnupiravir晶型及其制备方法
CN114560894B (zh) * 2022-03-11 2023-06-20 浙江乐普药业股份有限公司 一种抗新冠药物Molnupiravir的制备方法
CN114773405B (zh) * 2022-06-21 2022-09-23 和鼎（南京）医药技术有限公司 一种莫那比拉韦的制备方法
EP4633644A1 (en) * 2022-12-16 2025-10-22 Merck Sharp & Dohme LLC Solid dosage form of a small molecule antiviral and uses thereof
WO2024125604A1 (en) * 2022-12-16 2024-06-20 Suzhou Spring-Sea Bio-Pharmaceuticals Co. Ltd. Diester derivatives of n4-hydroxycytidine and use thereof
TW202440076A (zh) 2022-12-23 2024-10-16 日商明治製菓藥業股份有限公司 阿維菌素衍生物
WO2024144420A1 (ru) * 2022-12-28 2024-07-04 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Применение 5'-о-(3-фенилпропионил)-n4-гидроксицитидина для ингибирования репликации вируса гриппа in vitro и in vivo
WO2025003402A1 (en) 2023-06-28 2025-01-02 Immunic Ag Heteroaromatic dhodh inhibitors
TW202523336A (zh) * 2023-12-07 2025-06-16 中國化學製藥股份有限公司 醫藥溶液組合物及包含其之口腔霧化吸入劑型
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (279)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1325798A (en) 1970-09-24 1973-08-08 Upjohn Co Derivatives of 2,2-anhydro-ara-cytidine
GB1386334A (en) 1972-09-22 1975-03-05 Kohjin Co 2,2-cyclocytidine derivatives
DE2456547A1 (de) 1973-11-29 1975-08-14 Kohjin Co N hoch 4 -substituierte 2,2'-cyclocytidin-verbindungen
US4096324A (en) 1975-07-07 1978-06-20 The Upjohn Company Cytidine nucleoside compound
US5736531A (en) 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US5470838A (en) 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
KR920701230A (ko) 1989-06-05 1992-08-11 원본미기재 엑소뉴클레아제-내성 올리고뉴클레오티드 및 그 제조방법
WO1992009705A1 (en) 1990-11-23 1992-06-11 Gilead Sciences, Inc. Triplex-forming oligomers containing modified bases
RU2085557C1 (ru) 1991-09-30 1997-07-27 Санкио Компани Лимитед Производные нуклеозидов пиримидина или их фармацевтически приемлемые соли и способ их получения
CZ287745B6 (cs) 1991-10-11 2001-01-17 Ústav organické chemie a biochemie AV ČR Acyklické fosfonomethoxyalkylsubstituované alkenylové a alkinylové deriváty purinu a pyrimidinu
AU3222793A (en) 1991-11-26 1993-06-28 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US6057305A (en) 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
EP0695306A1 (en) 1993-04-19 1996-02-07 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5349947A (en) 1993-07-15 1994-09-27 Newhouse Michael T Dry powder inhaler and process that explosively discharges a dose of powder and gas from a soft plastic pillow
CA2171868A1 (en) 1993-09-17 1995-03-23 Petr Alexander Method for dosing therapeutic compounds
DE69435319D1 (de) 1993-09-17 2010-12-16 Gilead Sciences Inc Nukleotidanaloge
SG45864A1 (en) 1995-02-27 1999-04-27 Novel selective inhibitors of viral or bacterial neuraminidases
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
CN1238762A (zh) 1996-10-21 1999-12-15 吉里德科学公司 哌啶化合物
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6086376A (en) 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
KR20080021797A (ko) 2000-05-26 2008-03-07 이데닉스(케이만)리미티드 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
PT2251015E (pt) 2000-10-18 2013-04-15 Gilead Pharmasset Llc Nucleosídeos modificados para o tratamento de infeções virais e de proliferação celular anormal
EP2145965A1 (en) 2000-10-18 2010-01-20 Pharmasset, Inc. Multiplex quantification of nucleic acids in diseased cells
CA2743451A1 (en) 2000-10-18 2002-04-25 Pharmasset, Inc. Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
CA2594883A1 (en) 2001-04-30 2002-11-07 Trommsdorff Gmbh & Co. Kg Arzneimittel Pharmaceutically active uridine esters
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
US7049303B2 (en) 2001-11-07 2006-05-23 Medical Research Council Inhibition of viruses
US20050239054A1 (en) 2002-04-26 2005-10-27 Arimilli Murty N Method and compositions for identifying anti-HIV therapeutic compounds
JP4942915B2 (ja) 2002-04-26 2012-05-30 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖプロテアーゼ阻害剤化合物のホスホネートアナログの細胞蓄積
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
CN100536852C (zh) 2002-07-15 2009-09-09 基利得科学公司 L-fmau在制备联合治疗乙型肝炎病毒感染的药物中的应用
EP1541174A4 (en) 2002-09-11 2005-09-14 Michio Ishibashi MEDICINE OR COSMETIC PRODUCT
US20040191763A1 (en) 2002-10-01 2004-09-30 Gilead Sciences, Inc. HBV mutations associated with reduced susceptibility to adefovir
WO2004035577A2 (en) 2002-10-16 2004-04-29 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
US20040171860A1 (en) 2002-11-12 2004-09-02 Hong Zhao Novel acylating reagents
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
WO2004050613A2 (en) 2002-12-02 2004-06-17 Gilead Sciences, Inc. 2-substituted-3-propenamide derivatives and methods of using the same
DE602004014470D1 (de) 2003-01-14 2008-07-31 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
PT1628685E (pt) 2003-04-25 2011-03-16 Gilead Sciences Inc Análogos de fosfonatos antivirais
CN101410120A (zh) 2003-04-25 2009-04-15 吉里德科学公司 抗炎的膦酸酯化合物
KR20060028632A (ko) 2003-04-25 2006-03-30 길리애드 사이언시즈, 인코포레이티드 항염증 포스포네이트 화합물
WO2004096287A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
WO2005012324A2 (en) 2003-07-30 2005-02-10 Gilead Sciences, Inc. Nucleobase phosphonate analogs for antiviral treatment
DE602004021611D1 (de) 2003-09-19 2009-07-30 Gilead Sciences Inc Azachinolinolphosphonatverbindungen als integraseinhibitoren
RU2264409C2 (ru) 2003-10-01 2005-11-20 Государственный научный центр вирусологии и биотехнологии "Вектор" (ГНЦ ВБ "Вектор") 2`-амино-2`-дезоксинуклеозиды - ингибиторы репродукции вирусов кори и марбург
US7273717B2 (en) 2003-10-24 2007-09-25 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds with GS-9005 ester hydrolase B
EP1680435A1 (en) 2003-11-03 2006-07-19 Cognis IP Management GmbH Acyl ribonucleosides and acyl deoxyribonucleosides
NZ547907A (en) 2003-12-22 2010-07-30 Gilead Sciences Inc 4'-Substituted carbovir-and abacavir-derivatives as well as related compounds with HIV and HCV antiviral activity
EP2546254A1 (en) 2003-12-22 2013-01-16 K.U.Leuven Research & Development Imidazo[4,5-C]pyridine compounds and methods of antiviral treatment
RS51476B (sr) 2003-12-30 2011-04-30 Gilead Sciences, Inc. Fosfonati, monofosfonamidati, bisfosfonamidati za lečenje virusnih oboljenja
MXPA06007906A (es) 2004-01-12 2007-02-14 Gilead Sciences Inc Compuestos antivirales de fosfonato de pirimidilo y metodos de uso.
WO2005072748A1 (en) 2004-01-21 2005-08-11 Gilead Sciences, Inc. Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis
CA2562713A1 (en) 2004-04-14 2005-12-15 Gilead Sciences, Inc. Phosphonate analogs of hiv integrase inhibitor compounds
UA93354C2 (ru) 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
US20080311077A1 (en) 2004-07-16 2008-12-18 Kleem Chaudhary Antiviral Compounds
BRPI0512690A (pt) 2004-07-27 2007-11-27 Gilead Sciences Inc análogos de fosfonato de compostos inibidores de hiv
KR101238430B1 (ko) 2004-07-27 2013-02-28 길리애드 사이언시즈, 인코포레이티드 이미다조［4,5-ｄ］피리미딘, 그들의 용도 및 제조방법
DE102004051804A1 (de) * 2004-10-21 2006-04-27 Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) Beta-L-N4-Hydroxycytosin-Desoxynucleoside und ihre Verwendung als pharmazeutische Mittel zur Prophylaxe oder Therapie von viralen Erkrankungen
WO2006047661A2 (en) 2004-10-26 2006-05-04 Gilead Sciences, Inc. Phosphonate derivatives of mycophenolic acid
WO2006069193A2 (en) 2004-12-21 2006-06-29 Gilead Sciences, Inc. Imidazo[4,5-c]pyridine compound and method of antiviral treatment
WO2006091905A1 (en) 2005-02-25 2006-08-31 Gilead Sciences, Inc. Bicyclo (3.1.0) hexane derivatives as antiviral compounds
EP1888581A2 (en) 2005-05-16 2008-02-20 Gilead Sciences, Inc. Hiv-integrase inhibitor compounds
EP2581440B1 (en) 2005-06-08 2016-03-16 The University of North Carolina At Chapel Hill Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics
TWI389908B (zh) 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
TW200738742A (en) 2005-07-14 2007-10-16 Gilead Sciences Inc Antiviral compounds
US20070128625A1 (en) 2005-07-25 2007-06-07 Gilead Sciences, Llc Drug-resistant mutants of hepatitis C virus
AU2006272521A1 (en) 2005-07-27 2007-02-01 Gilead Sciences, Inc. Antiviral phosphonate conjugates for inhibition of HIV
MX2008002165A (es) 2005-08-16 2008-04-29 Irm Llc Compuestos y composiciones como inhibidores de la proteina cinasa.
DE602006003913D1 (de) 2005-09-22 2009-01-08 Hoffmann La Roche Selektive o-acylierung von nukleosiden
CA2847871C (en) 2005-12-30 2016-07-26 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
US20110065631A1 (en) 2006-03-29 2011-03-17 Gilead Sciences, Inc Process for preparation of hiv protease inhibitors
WO2008003149A2 (en) 2006-07-06 2008-01-10 Gilead Sciences , Inc. Substituted pteridines for the treatment and prevention of viral infections
EA025845B1 (ru) 2006-07-07 2017-02-28 Джилид Сайэнс, Инк. Модуляторы фармакокинетических свойств лекарственных средств
SG175604A1 (en) 2006-07-07 2011-11-28 Gilead Sciences Inc Novel pyridazine compound and use thereof
US8338593B2 (en) 2006-07-07 2012-12-25 Gilead Sciences, Inc. Modulators of toll-like receptor 7
WO2008005542A2 (en) 2006-07-07 2008-01-10 Gilead Sciences, Inc., Antiviral phosphinate compounds
WO2008009079A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
US8338435B2 (en) 2006-07-20 2012-12-25 Gilead Sciences, Inc. Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
WO2008009078A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
WO2008009077A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
ES2574831T3 (es) 2006-07-21 2016-06-22 Gilead Sciences, Inc. Inhibidores de la proteasa antivirales
WO2008011116A2 (en) 2006-07-21 2008-01-24 Gilead Sciences, Inc. Aza-peptide protease inhibitors
EP2044037A2 (en) 2006-07-24 2009-04-08 Gilead Sciences, Inc. Hiv reverse transcriptase inhibitors
EP2069356A1 (en) 2006-07-24 2009-06-17 Gilead Sciences, Inc. Bisfuranyl protease inhibitors
CA2664156A1 (en) 2006-09-27 2008-04-03 Coley Pharmaceutical Group, Inc. Compositions of tlr ligands and antivirals
AU2007352397B2 (en) 2006-12-14 2013-09-26 Gilead Sciences, Inc. Viral inhibitors
US8637531B2 (en) 2006-12-26 2014-01-28 Gilead Sciences, Inc. Pyrido(3,2-d)pyridmidines useful for treating viral infections
WO2008077649A1 (en) 2006-12-26 2008-07-03 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines useful for treating viral infectons
TW200840584A (en) 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
WO2008100447A2 (en) 2007-02-09 2008-08-21 Gilead Sciences, Inc. Nucleoside analogs for antiviral treatment
EA019893B1 (ru) 2007-02-23 2014-07-30 Джилид Сайэнс, Инк. Фармацевтическая композиция и способ лечения вич-инфекции
EP2142178B1 (en) 2007-03-29 2012-01-11 F. Hoffmann-La Roche AG Pharmaceutical composition and process
JP5547067B2 (ja) 2007-06-29 2014-07-09 ギリアード サイエンシーズ， インコーポレイテッド 治療組成物およびその使用
US20090047252A1 (en) 2007-06-29 2009-02-19 Gilead Sciences, Inc. Antiviral compounds
JP5547066B2 (ja) 2007-06-29 2014-07-09 ギリアード サイエンシーズ， インコーポレイテッド 治療用組成物およびその使用
US8354421B2 (en) 2007-06-29 2013-01-15 Korea Research Insitute Of Chemical Technology HIV reverse transcriptase inhibitors
BRPI0813733A2 (pt) 2007-06-29 2019-11-05 Gilead Sciences Inc composto com atividade inibidora de hcv, sua composição farmacêutica e seu uso.
JP5395068B2 (ja) 2007-06-29 2014-01-22 ギリアード サイエンシーズ， インコーポレイテッド トール様受容体７の調節物質としてのプリン誘導体およびその使用
WO2009005674A2 (en) 2007-06-29 2009-01-08 Gilead Sciences, Inc. Novel hiv reverse transcriptase inhibitors
CN101790524B (zh) 2007-06-29 2014-07-16 吉里德科学公司 抗病毒化合物
UA99466C2 (en) 2007-07-06 2012-08-27 Гилиад Сайенсиз, Инк. Crystalline pyridazine compound
WO2009058800A2 (en) 2007-10-29 2009-05-07 President And Fellows Of Harvard College Synthesis of nucleosides
US20100298256A1 (en) 2007-12-27 2010-11-25 Steven Dong Antiviral compounds
PT2231628E (pt) 2008-01-04 2015-12-29 Gilead Sciences Inc Inibidores de citocromo p450
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
AP3076A (en) 2008-04-23 2014-12-31 Gilead Sciences Inc Carba-nucleoside analogs for antiviral treatment
WO2009143011A1 (en) 2008-05-20 2009-11-26 Novartis Ag Antiviral compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions
US8536187B2 (en) 2008-07-03 2013-09-17 Gilead Sciences, Inc. 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections
PT2307435E (pt) 2008-07-08 2012-09-19 Gilead Sciences Inc Sais de compostos inibidores de vih
EP2321319B1 (en) 2008-07-25 2012-03-14 Gilead Sciences, Inc. Antiviral compounds
CN103497192B (zh) 2008-12-09 2015-09-23 吉里德科学公司 Toll样受体调节剂
TW201034663A (en) 2008-12-19 2010-10-01 Gilead Sciences Inc HCV NS3 protease inhibitors
EP2367813A1 (en) 2008-12-22 2011-09-28 Gilead Sciences, Inc. Antiviral compounds
CN102348713B (zh) 2009-02-10 2015-12-02 吉里德科学公司 用于抗病毒治疗的carba-核苷类似物
KR20180028070A (ko) 2009-05-13 2018-03-15 길리애드 파마셋 엘엘씨 항바이러스 화합물
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
AR077125A1 (es) 2009-06-23 2011-08-03 Gilead Sciences Inc Combinaciones farmaceuticas utiles para tratar el vhc
UY32721A (es) 2009-06-23 2011-01-31 Gilead Sciences Ltd Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados
US20100324060A1 (en) 2009-06-23 2010-12-23 Gilead Sciences, Inc. Pharmaceutical compositions useful for treating hcv
WO2011005842A1 (en) 2009-07-09 2011-01-13 Gilead Sciences, Inc. Anti-rsv compounds
TW201116525A (en) 2009-07-21 2011-05-16 Gilead Sciences Inc Inhibitors of flaviviridae viruses
NZ598208A (en) 2009-09-09 2014-02-28 Gilead Sciences Inc Inhibitors of flaviviridae viruses
JP5763077B2 (ja) 2009-09-14 2015-08-12 ギリアード サイエンシーズ， インコーポレイテッド トール様受容体のモジュレーター
EA201200525A1 (ru) 2009-09-21 2012-09-28 Гайлид Сайэнсиз, Инк. 2'-фторзамещенные карба-нуклеозидные аналоги для противовирусного лечения
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
SI2491035T1 (sl) 2009-10-22 2017-10-30 Gilead Sciences, Inc. Derivati purina ali deazapurina uporabni za zdravljenje (med drugimi) virusnih okužb
WO2011079016A1 (en) 2009-12-22 2011-06-30 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
ES2543105T3 (es) 2010-01-15 2015-08-14 Gilead Sciences, Inc. Inhibidores de virus flaviviridae
JP5868872B2 (ja) 2010-01-15 2016-02-24 ギリアード サイエンシーズ， インコーポレイテッド フラビウイルス科ウイルスのインヒビター
RU2556991C2 (ru) 2010-01-28 2015-07-20 Рибосайенс Ллк 4'-азидонуклеозиды, активные в отношении hcv
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
WO2011143106A1 (en) 2010-05-10 2011-11-17 Gilead Sciences, Inc. Bi - functional pyrazolopyridine compounds
EP2569285A1 (en) 2010-05-10 2013-03-20 Gilead Sciences, Inc. Bifunctional quinoline derivatives
CA2797872A1 (en) 2010-05-21 2011-11-24 Gilead Sciences, Inc. Heterocyclic flaviviridae virus inhibitors
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
TW201210597A (en) 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
TW201211047A (en) 2010-06-10 2012-03-16 Gilead Sciences Inc Methods for treating HCV
PT2579871E (pt) 2010-06-11 2015-11-17 Gilead Sciences Inc Formulações antivirais tópicas para a prevenção da transmissão do hsv-2
US8486938B2 (en) 2010-06-24 2013-07-16 Gilead Sciences, Inc. Pyrazolo[1,5-a]pyrimidines for antiviral treatment
NZ604716A (en) 2010-07-02 2014-12-24 Gilead Sciences Inc 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
MA34397B1 (fr) 2010-07-02 2013-07-03 Gilead Sciences Inc Dérivés d'acide napht-2-ylacétique dans le traitement du sida
EP2596004B1 (en) 2010-07-19 2014-09-10 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
PT2595980E (pt) 2010-07-22 2014-11-27 Gilead Sciences Inc Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae
CN102351931B (zh) 2010-09-07 2014-01-22 河南省科学院高新技术研究中心 嘧啶核苷衍生物、合成方法及其在制备抗肿瘤、抗病毒药物中的应用
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
CA2807496C (en) 2010-09-20 2019-01-22 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
AU2011328980B2 (en) 2010-11-17 2015-07-30 Gilead Sciences, Inc. Antiviral compounds
TWI556840B (zh) 2010-11-19 2016-11-11 吉李德科學股份有限公司 治療用組成物
AR084217A1 (es) 2010-12-10 2013-05-02 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
TW201701876A (zh) 2010-12-20 2017-01-16 吉李德科學股份有限公司 治療ｃ型肝炎病毒（ｈｃｖ）之方法
WO2012088156A1 (en) 2010-12-21 2012-06-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450
US20130274254A1 (en) 2010-12-21 2013-10-17 Gilead Sciences, Inc. Inhibitors of cytochrome p450 (cyp3a4)
WO2012088153A1 (en) 2010-12-21 2012-06-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450
WO2012138669A1 (en) 2011-04-04 2012-10-11 Gilead Sciences, Inc. Solid state forms of hiv inhibitor
CA2830838A1 (en) 2011-04-04 2012-11-10 Gilead Sciences, Inc. Process for the preparation of an hiv integrase inhibitor
CA2830689A1 (en) 2011-04-13 2012-10-18 Gilead Sciences, Inc. 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment
AP2013007249A0 (en) 2011-04-21 2013-11-30 Gilead Sciences Inc Benzothiazole compounds and their pharmaceutical use
US20140187771A1 (en) 2011-05-02 2014-07-03 Gilead Sciences, Inc. Amorphous solid salts
WO2013006722A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Hcv genotype 3 replicons
WO2013006738A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
MX2014000123A (es) 2011-07-06 2014-02-17 Gilead Sciences Inc Replicones de genotipo 4 de hcv.
ES2561888T3 (es) 2011-07-13 2016-03-01 Gilead Sciences, Inc. Derivados de ácido tiofeno-2-carboxílico útiles como inhibidores de virus Flaviviridae
KR101612642B1 (ko) 2011-08-16 2016-04-14 길리애드 사이언시즈, 인코포레이티드 테노포비어 알라펜아미드 헤미푸마레이트
CA2840242C (en) 2011-09-16 2019-03-26 Gilead Sciences, Inc. Methods for treating hcv
AU2012332827A1 (en) 2011-10-31 2014-05-15 Gilead Pharmasset Llc Methods and compositions for treating hepatitis C virus
KR20210043734A (ko) 2011-11-16 2021-04-21 길리애드 파마셋 엘엘씨 항바이러스성 화합물로서의 축합된 이미다졸릴이미다졸
EP2785340B1 (en) 2011-11-29 2020-07-15 Gilead Pharmasset LLC Compositions and methods for treating hepatitis c virus
WO2013090929A1 (en) 2011-12-15 2013-06-20 Gilead Sciences, Inc. Amino quinoline derivatives inhibitors of hcv
WO2013090840A1 (en) 2011-12-15 2013-06-20 Gilead Sciences, Inc. 2 -amino- pyrido [3, 2 -d] pyrimidine derivatives as hcv inhibitors
AU2012358994A1 (en) 2011-12-20 2014-08-07 Gilead Sciences, Inc. Pharmaceutical compositions and methods for treating gastrointestinal infections and disorders
CA2858096C (en) 2011-12-22 2020-06-23 Gilead Sciences, Inc. Pyrazolo[1,5-a]pyrimidines as antiviral agents
PL2794627T3 (pl) 2011-12-22 2019-04-30 Alios Biopharma Inc Podstawione nukleozydy, nukleotydy i ich analogi
WO2013103738A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. Napthalene acetic acid derivatives against hiv infection
WO2013103724A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids
EP2802315A1 (en) 2012-01-12 2014-11-19 Gilead Sciences, Inc. Pharmaceutical compositions and methods for their preparation
HK1204914A1 (en) 2012-02-03 2015-12-11 Gilead Sciences, Inc. Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
WO2013115916A1 (en) 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections
SI2834258T1 (sl) 2012-03-13 2017-04-26 Gilead Sciences, Inc. 2'-substituirani karba-nukleozidni analogi za protivirusno zdravljenje
UA113980C2 (uk) 2012-03-21 2017-04-10 Аліос Біофарма, Інк. Заміщені нуклеозиди, нуклеотиди і їх аналоги
CN106986869A (zh) 2012-04-17 2017-07-28 吉利德科学公司 用于抗病毒治疗的化合物和方法
SG11201401189WA (en) 2012-04-20 2014-09-26 Gilead Sciences Inc Benzothiazol- 6 -yl acetic acid derivatives and their use for treating an hiv infection
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US9079887B2 (en) 2012-05-16 2015-07-14 Gilead Sciences, Inc. Antiviral compounds
HK1211285A1 (en) 2012-06-08 2016-05-20 吉利德科学公司 Macrocyclic inhibitors of flaviviridae viruses
PL2859009T3 (pl) 2012-06-08 2018-03-30 Gilead Sciences, Inc. Makrocykliczne inhibitory wirusów flaviviridae
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
US8841340B2 (en) 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
WO2014055618A1 (en) 2012-10-03 2014-04-10 Gilead Sciences, Inc. Solid state forms of hiv inhibitor: hemi-succinate of (2s)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid)
RU2015119647A (ru) 2012-10-26 2016-12-20 Конинклейке Филипс Н.В. Автостереоскопическое дисплейное устройство, имеющее просветный режим работы
WO2014070771A1 (en) 2012-10-29 2014-05-08 Rfs Pharma, Llc Pyrimidine nucleotides and their monophosphate prodrugs for treatment of viral infections and cancer
KR20150074179A (ko) 2012-10-30 2015-07-01 길리애드 사이언시즈, 인코포레이티드 리실 옥시다제-유사 2 (loxl2)와 관련된 치료 및 진단 방법
EP2917340A1 (en) 2012-11-07 2015-09-16 Gilead Sciences, Inc. Hcv genotype 6 replicons
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
AU2013361401C1 (en) 2012-12-21 2018-08-09 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
EA201590943A1 (ru) 2012-12-21 2016-01-29 Алиос Биофарма, Инк. Замещенные нуклеозиды, нуклеотиды и их аналоги
NZ631762A (en) 2013-01-09 2017-02-24 Gilead Sciences Inc 5-membered heteroaryls and their use as antiviral agents
CA2897268C (en) 2013-01-09 2018-12-04 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
WO2014124430A1 (en) 2013-02-11 2014-08-14 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
US20140273023A1 (en) 2013-03-15 2014-09-18 Saladax Biomedical Inc. Gemcitabine immunoassay
ES2735355T3 (es) 2013-03-15 2019-12-18 Gilead Sciences Inc Inhibidores macrocíclicos y bicíclicos de virus de hepatitis C
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
AU2014250764A1 (en) 2013-04-12 2015-10-29 Achillion Pharmaceuticals, Inc. Deuterated nucleoside prodrugs useful for treating HCV
AU2014265293B2 (en) 2013-05-16 2019-07-18 Riboscience Llc 4'-Fluoro-2'-methyl substituted nucleoside derivatives
ES2952714T3 (es) 2013-06-26 2023-11-03 Janssen Pharmaceuticals Inc Nucleósidos sustituidos, nucleótidos y análogos de los mismos
US20150072418A1 (en) 2013-08-16 2015-03-12 Gilead Sciences, Inc. Hcv genotype 4d replicons
EP3043803B1 (en) 2013-09-11 2022-04-27 Emory University Nucleotide and nucleoside compositions and their uses
SG10201804835VA (en) 2013-10-11 2018-07-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015084741A2 (en) 2013-12-02 2015-06-11 Gilead Pharmasset Llc Methods of treating hepatitis c virus infection in subjects with cirrhosis
TW201609785A (zh) 2013-12-23 2016-03-16 吉李德製藥公司 固體型之抗病毒化合物
EP3087086B1 (en) 2013-12-23 2018-11-07 Gilead Sciences, Inc. Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide
TWI660965B (zh) 2014-01-15 2019-06-01 美商基利科學股份有限公司 泰諾福韋之固體形式
US10441567B2 (en) 2014-01-17 2019-10-15 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
WO2015120057A1 (en) 2014-02-05 2015-08-13 Gilead Sciences, Inc. Pharmaceutical combinations against co-infection with hiv and tuberculosis
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
WO2015179448A1 (en) 2014-05-21 2015-11-26 Gilead Sciences, Inc. Therapeutic compounds
EP3154985B1 (en) 2014-06-12 2018-06-06 Gilead Sciences, Inc. Antiviral compounds
AU2015274696B2 (en) 2014-06-13 2018-09-27 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
CA2952044C (en) 2014-06-13 2019-01-29 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
CN106660994A (zh) 2014-06-13 2017-05-10 吉利德科学公司 磷脂酰肌醇3‑激酶抑制剂
NZ726055A (en) 2014-06-13 2018-04-27 Gilead Sciences Inc Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors
SG11201610095SA (en) 2014-06-13 2016-12-29 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
SG11201610599TA (en) 2014-06-24 2017-01-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2015200205A1 (en) 2014-06-24 2015-12-30 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN105288635A (zh) 2014-06-26 2016-02-03 昆明积大制药股份有限公司 一种含有阿糖胞苷5’-0-氨基酸酯的药物组合物
JP6522732B2 (ja) 2014-07-11 2019-05-29 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを治療するためのトール様受容体の調節因子
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
TWI673283B (zh) 2014-08-21 2019-10-01 美商基利科學股份有限公司 ２’－氯胺基嘧啶酮及嘧啶二酮核苷類
PT3186239T (pt) 2014-08-29 2019-01-10 Gilead Sciences Inc Agentes antirretrovirais
US20160067255A1 (en) 2014-09-04 2016-03-10 Gilead Sciences, Inc. Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
ES2705709T3 (es) 2014-12-24 2019-03-26 Gilead Sciences Inc Compuestos de isoquinolina para el tratamiento del VIH
TWI770552B (zh) 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
CN107207498B (zh) 2014-12-24 2020-03-24 吉利德科学公司 用于治疗hiv的稠合嘧啶化合物
CN107427529A (zh) * 2014-12-26 2017-12-01 埃莫里大学 N4‑羟基胞苷和衍生物及与其相关的抗病毒用途
WO2016134054A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
PH12021551982A1 (en) 2015-03-04 2022-09-05 Gilead Sciences Inc Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
PT3466490T (pt) 2015-04-02 2020-12-24 Gilead Sciences Inc Compostos de carbamoilpiridona policíclicos e sua utilização farmacêutica
JP2018511621A (ja) 2015-04-14 2018-04-26 ギリアード サイエンシーズ， インコーポレイテッド Ｂ型肝炎ウイルスを処置する方法
EP3294732B1 (en) 2015-05-15 2019-09-25 Gilead Sciences, Inc. Benzimidazole and imadazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase
WO2016205141A1 (en) 2015-06-17 2016-12-22 Gilead Sciences, Inc. Co-crystals, salts and solid forms of tenofovir alafenamide
CA2921336A1 (en) 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
US20170000807A1 (en) 2015-06-30 2017-01-05 Gilead Sciences, Inc. Pharmaceutical formulations
JP2018523665A (ja) 2015-08-06 2018-08-23 キメリックス インコーポレイテッド 抗ウイルス剤として有用なピロロピリミジンヌクレオシドおよびその類縁体
US20210292327A1 (en) 2015-08-26 2021-09-23 Gilead Sciences, Inc. Deuterated toll-like receptor modulators
WO2017040895A1 (en) 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral compounds
WO2017040896A1 (en) 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral compounds
AU2016322763A1 (en) 2015-09-15 2018-04-19 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of HIV
PL3349758T3 (pl) 2015-09-16 2022-09-12 Gilead Sciences, Inc. Sposoby leczenia zakażeń wirusami arenaviridae
EP3356355B1 (en) 2015-09-30 2020-05-13 Gilead Sciences, Inc. Compounds and combinations for the treatment of hiv
JP2018530550A (ja) 2015-10-01 2018-10-18 ギリアド サイエンシズ， インコーポレイテッド 癌を治療するためのｂｔｋ阻害剤とチェックポイント阻害剤との組合せ
JP6621933B2 (ja) 2015-11-09 2019-12-18 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルスを処置するための治療組成物
JP6732915B2 (ja) 2015-12-15 2020-07-29 ギリアード サイエンシーズ， インコーポレイテッド ヒト免疫不全ウイルス中和抗体
JP2019500368A (ja) 2015-12-17 2019-01-10 ギリアード サイエンシーズ， インコーポレイテッド Ｔａｎｋ結合キナーゼ阻害剤化合物
WO2017106710A1 (en) 2015-12-17 2017-06-22 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
US10874683B2 (en) 2016-03-10 2020-12-29 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US11963972B2 (en) * 2016-03-23 2024-04-23 Emory University Antiviral agents and nucleoside analogs for treatment of Zika virus
WO2017176336A1 (en) 2016-04-08 2017-10-12 Krystal Biotech, LLC Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
WO2017184668A1 (en) 2016-04-20 2017-10-26 Gilead Sciences, Inc. Methods for treating flaviviridae virus infections
WO2017184670A2 (en) 2016-04-22 2017-10-26 Gilead Sciences, Inc. Methods for treating zika virus infections
MX2018014377A (es) 2016-05-27 2019-03-14 Gilead Sciences Inc Metodos para tratar infecciones por virus de hepatitis b usando inhibidores de proteina no estructural 5a (ns5a), proteina no estructural 5b (ns5b) o proteina no estructural 3 (ns3).
BR102017010009A2 (pt) 2016-05-27 2017-12-12 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
EP3471738A4 (en) 2016-06-20 2020-01-01 Merck Sharp & Dohme Corp. CYCLIC PHOSPHONATE-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR USE THEREOF FOR TREATING VIRUS DISEASES
WO2017223268A1 (en) 2016-06-22 2017-12-28 Yale University COMPOSITIONS AND METHODS OF RESENSITIZING CELLS TO BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN INHIBITORS (BETi)
ES2995458T3 (en) * 2017-12-07 2025-02-10 Univ Emory N4-hydroxycytidine derivative and anti-viral uses related thereto
CN119633010A (zh) 2018-03-07 2025-03-18 埃默里大学 含4′-卤素的核苷酸和核苷治疗组合物以及其相关用途
PE20230466A1 (es) 2020-02-07 2023-03-14 Univ Emory N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos

Also Published As

Publication number Publication date
AU2018378832A1 (en) 2020-05-14
KR102248165B1 (ko) 2021-05-06
AU2021206866B2 (en) 2024-04-18
AU2018378832B2 (en) 2021-05-20
US20200276219A1 (en) 2020-09-03
CA3082191A1 (en) 2019-06-13
JP7179372B2 (ja) 2022-11-29
PH12020550607A1 (en) 2021-02-15
HUE069306T2 (hu) 2025-02-28
EP4491232A3 (en) 2025-03-12
FI3706762T3 (fi) 2024-12-13
BR122022008466B1 (pt) 2023-12-05
SA520412305B1 (ar) 2024-08-07
ZA202002849B (en) 2023-01-25
PH12022550371A1 (en) 2023-05-03
KR20210050594A (ko) 2021-05-07
IL274155A (en) 2020-05-31
MX2020005392A (es) 2020-12-07
US11331331B2 (en) 2022-05-17
SG11202004403QA (en) 2020-06-29
PT3706762T (pt) 2024-12-05
US20240189335A1 (en) 2024-06-13
CN118477088A (zh) 2024-08-13
GB202008628D0 (en) 2020-07-22
US11903959B2 (en) 2024-02-20
JP2023082213A (ja) 2023-06-13
US20220016153A1 (en) 2022-01-20
AU2021206866A1 (en) 2021-08-12
BR112020010581A2 (pt) 2020-11-10
GB2590198A (en) 2021-06-23
GB2581936A (en) 2020-09-02
IL274155B (en) 2021-07-29
RU2020116571A3 (enExample) 2021-11-22
EP4491232A2 (en) 2025-01-15
WO2019113462A1 (en) 2019-06-13
PL3706762T3 (pl) 2025-02-10
JP2021042235A (ja) 2021-03-18
LT3706762T (lt) 2024-12-27
JP2021165280A (ja) 2021-10-14
DK3706762T3 (da) 2024-12-16
US12329770B2 (en) 2025-06-17
EP3706762B1 (en) 2024-10-16
KR20200071119A (ko) 2020-06-18
EP3706762A1 (en) 2020-09-16
JP7305205B2 (ja) 2023-07-10
KR20240011880A (ko) 2024-01-26
CN111372592A (zh) 2020-07-03
JP2021505530A (ja) 2021-02-18
ES2995458T3 (en) 2025-02-10
RU2020116571A (ru) 2021-11-22
RS66222B1 (sr) 2024-12-31
GB2581936B (en) 2021-02-10
HRP20241620T1 (hr) 2025-01-31
MX2023008882A (es) 2023-08-09
CA3082191C (en) 2021-09-21
GB202020498D0 (en) 2021-02-03
EP3706762A4 (en) 2021-09-01
KR102626210B1 (ko) 2024-01-18
SI3706762T1 (sl) 2025-03-31
GB2590198B (en) 2022-02-23
IL284100A (en) 2021-07-29
AU2018378832B9 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
JP6804790B1 (ja) Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
US11628181B2 (en) N4-hydroxycytidine and derivatives and anti-viral uses related thereto
JP7504517B2 (ja) ヌクレオシド誘導体及びその使用方法
US10874683B2 (en) N4-hydroxycytidine and derivatives and anti-viral uses related thereto
KR20200140274A (ko) 4'-할로겐 함유 뉴클레오티드 및 뉴클레오시드 치료 조성물 및 이와 관련된 용도
WO2022174194A1 (en) 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
HK40038030A (en) N4-hydroxycytidine derivative and anti-viral uses related thereto
HK40038030B (en) N4-hydroxycytidine derivative and anti-viral uses related thereto
BR112020010581B1 (pt) Composição farmacêutica
BR122021012627B1 (pt) Composição farmacêutica
EA045093B1 (ru) Производное n4-гидроксицитидина, содержащая его фармацевтическая композиция и связанные с этим противовирусные применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200615

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200615

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20201009

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201027

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201126

R150 Certificate of patent or registration of utility model

Ref document number: 6804790

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250